|本期目录/Table of Contents|

[1]沈洋,孙韬,李泉旺,等.中药联合氩氦刀“绿色治疗”模式对44例老年晚期非小细胞肺癌患者的生存影响[J].环球中医药,2016,9(01):29-33.[doi:10.3969/j.issn.1674-1749.2016.01.007]
　SHEN Yang,SUN Tao,LI Quan-wang,et al.Survival effect of 44 cases of elderly patients with advanced NSCLC: A “Green Therapeutic” mode combined with both percutaneous cryoablation and TCM herbal formula[J].,2016,9(01):29-33.[doi:10.3969/j.issn.1674-1749.2016.01.007]
点击复制

中药联合氩氦刀“绿色治疗”模式对44例老年晚期 非小细胞肺癌患者的生存影响()
     
分享到：

《环球中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
第9卷
期数:
2016年01期
页码:
29-33
栏目:
论著
出版日期:
2016-01-06

文章信息/Info

Title:
Survival effect of 44 cases of elderly patients with advanced NSCLC: A “Green Therapeutic” mode combined with both percutaneous cryoablation and TCM herbal formula
作者:
沈洋; 孙韬; 李泉旺; 姜敏; 刘传波; 孟繁中; 胡凯文
100078 北京中医药大学第二临床医学院[沈洋(博士研究生)、孟繁中(硕士研究生)];
北京中医药大学东方医院肿瘤科(孙韬、李泉旺、姜敏、刘传波、胡凯文)
Author(s):
SHEN Yang; SUN Tao; LI Quan-wang; et al.
Oncology Department, Dongfang Hospital,Beijing University of Chinese Medicine, Beijing 100078, China
关键词:
中药;  氩氦刀;  老年;  晚期;  非小细胞肺癌;  生存影响
Keywords:
TCM herbal formula;  Percutaneous cryoablation;  Elderly;  Advanced;  Non-small cell lung cancer;  Survival effect
分类号:
R242
DOI:
10.3969/j.issn.1674-1749.2016.01.007
文献标志码:
A
摘要:
目的 对老年晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者进行中药汤剂口服联合氩氦刀冷冻治疗的生存影响进行临床观察分析。方法 采用前瞻性研究方法,共观察90例老年晚期NSCLC患者氩氦刀冷冻前后生活质量的变化、局部瘤灶的复发转移情况及生存期并进行统计分析。结果 治疗组、对照组的中位生存期分别为14个月、11个月。根据Karnofsky功能状态评分标准及生活质量评分标准(QOL),在患者术前和术后3个月、6个月生活质量变化,局部瘤灶转移率,氩氦刀术后中位生存期及1年、18个月的生存率方面,P<0.05,治疗组优于对照组。结论 中药联合氩氦刀的“绿色治疗”模式对44例老年晚期NSCLC患者的生存影响方面具有明显意义。
Abstract:
Objective To observe the survival effect of TCM herbal formula with percutaneous cryoablation therapy in elderly advanced non-small cell lung cancer. Methods 90 patients with elderly advanced non-small cell lung cancer(NSCLC)were divided into treatment group(n=44)and control group(n=46)according to the patients' wishes to observe, statistical recordings of changes of life quality, the probability of tumor recurrence, metastasis as well as lifetime. Results The survival median in the treatment group and control group is 14 months, 11 months respectively. According to Karnofsky functional status grading standard and quality of life marking standard(QOL), the treatment group was superior to control group in the quality of life changes of preoperative and postoperative 3 months, 6 months, the metastasis rate local tumor,the median surial time after percutaneous cryoablation and the survival of 1 year, 18 months(P<0.05).Conclusions The “Green Therapeutic” mode combined with TCM herbal formula and percutaneous cryoablation has significant meaning in the survival effect for 44 cases of elderly patients with advanced NSCLC.

参考文献/References:

[1] Anglim PP,Alonzo TA,Laird-offringa IA. DNA Methylation-based biomarkers for early detection of non-small cell lung cancer:an update[J]. MolCancer,2008,7(1):81.
[2] 周际昌.实用肿瘤内科学[M].北京.人民卫生出版社,2000:34.
[3] 张天泽,徐光炜.肿瘤学[M].天津:天津科学技术,2005:2791.
[4] Geridelli C,Langer C,Mauibe P,et al. Lung cancer in the elderly[J]. J Clin Oncol,2007,25(14):1898-1907.
[5] Parkin DM,Bray F,Ferlay J,et al. Global cancer statistics[J]. CA Cancer J clip,2005,(55):74-108.
[6] Montazeri A,Mikoy R,Hole D,et al. Quality of life in lung cancer patients as a important prognostic factor[J]. Lung Cancer,2001,3(2-3):223-240.
[7] Kiely BE,Alam-M,Blinman p,et al. Estimating typical,best-case and worst-case life expectancy scenarios for patients starting chemotherapy for advanced non-small-cell lung cancer:A systematic review of contemporary randomized trials[J]. Lung Cancer,2012,77(3),537-544.
[8] Wao H,Mhaskar R,Kumar A,et al. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis[J]. Syst Rev,2013,(2),2-10.
[9] de Marinis F,Pereira JR,Fossella F,et al. Lung Cancer Symptom Scale outcomes in relation to standard efficacy measures:an analysis of the phase III study of pemetrexed versus docetaxel in advanced non-small cell lung cancer[J]. J Thorac Oncol,2008,3(1):30-36.
[10] 胡凯文,郑洪霞,齐静,等.浙贝母碱逆转白血病细胞多药耐药的研究[J]. 中华血液学杂志,1999,(12):33-34.

相似文献/References:

[1]王利芬.中药联合甲氨蝶呤治疗输卵管妊娠142例[J].环球中医药,2013,6(04):284.
[2]王淙悦 喻明 王华伟等.中药应用于肿瘤转移的20年用药规律探索[J].环球中医药,2014,7(02):113.
[3]崔娣 胡晓冬 夏清青.中药联合化疗治疗晚期非小细胞肺癌疗效及对患者生存期的影响[J].环球中医药,2014,7(03):219.
[4]秦兰.宫颈癌术后同步放化疗辅以中药内服的临床观察及毒副反应分析[J].环球中医药,2013,6(06):424.
　QIN Lan..Clinical effect and toxicity reaction of radiotherapy and chemotherapy combined with Chinese medicine in treating cervical cancer[J].,2013,6(01):424.
[5]徐和,戴领,沈成英,等.基于MTT法的波棱瓜子抗肝纤维化用量初步研究[J].环球中医药,2013,6(08):589.
　XU He,DAI Ling,SHEN Cheng ying,et al.Research on the administration dosage for antihepatic fibrosis of Herpetospermum caudigerum based on MTT assay[J].,2013,6(01):589.
[6]刘永衡,郎娜,陈秀,等.中药复方逆转肿瘤多药耐药研究近况及相关PI3K/AKT/NF_(-κ)B分子通路分析[J].环球中医药,2013,6(09):704.
　LIU Yong heng,LANG Na,CHEN Xiu..Traditional Chinese medicine compound in reversal of multidrug resistance in tumors and the analysis on PI3K/AKT/NFκB molecular pathway[J].,2013,6(01):704.
[7]王雪冰,张伟,李淼,等.中药外治干预化疗相关消化道反应的疗效观察[J].环球中医药,2013,6(11):858.
[8]李炯辉,刘莹.中药治疗肿瘤放射治疗后损伤的临床研究进展[J].环球中医药,2012,5(11):869.
　LI Jiong hui,LIU Ying..Clinical research progress of TCM in treating injury after radiotherapy of tumor[J].,2012,5(01):869.
[9]王秀霞,梁玲,薛会灵,等.近5年中药治疗原发性痛经临床研究进展[J].环球中医药,2012,5(02):157.
　WANG Xiu-xia,LIANG Ling,XUE Hui-ling,et al.Study progression on treatment of primary dysmenorrhea by Chinese herbs in recent five years[J].,2012,5(01):157.
[10]吴海建 高瑞岭 张俊清等.中西医结合治疗女阴湿疹60例[J].环球中医药,2014,7(07):542.

备注/Memo

备注/Memo:
基金项目: 北京中医药大学中西医结合肿瘤治疗协同创新中心(2013-XRCX-05)
作者单位: 100078 北京中医药大学第二临床医学院[沈洋(博士研究生)、孟繁中(硕士研究生)]; 北京中医药大学东方医院肿瘤科(孙韬、李泉旺、姜敏、刘传波、胡凯文)
作者简介: 沈洋(1986- ),2014级在读博士研究生。研究方向:中西医结合防治肿瘤。E-mail:Doctor_Alex@163.com
通讯作者: 胡凯文(1964- ),博士,教授,主任医师,博士研究生导师。中国生命关怀协会副会长,中华中医药学会肿瘤专业委员会副主任委员,中华冷冻治疗学会副主任委员兼秘书,北京中医药学会肿瘤专业委员会副主任委员,中国宋庆龄基金会理事,世界中医药学会联合会肿瘤专业委员会理事。研究方向:中西医结合防治肿瘤。E-mail: kaiwenh@163.com
更新日期/Last Update: 2016-01-06